PharmaShots | Incisive News in 3 Shots

Subscribe Now

Access Program

AveXis Receives EC's Conditional Approval and Activates “Day One” Access Program for Zolgensma (onasemnogene abeparvovec) to Treat Spinal Muscular Atrophy

AveXis Receives EC's Conditional Approval and Activates “Day One” Access Program for Zolgensma (onasemnogene abeparvovec) to Treat...

May 20, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us